[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100545041":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":29,"centralContacts":34,"locations":40,"responsibleParty":74,"collaborators":77,"id":81,"slug":82,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":83,"sex":89,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":28,"studyType":95,"phases":96,"briefSummary":98,"conditions":99,"keywords":108,"overallStatus":43,"whyStopped":28,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":134},{"fullName":5,"class":6},"Brigham and Women's Hospital","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"TMS to random PFC location 1","EXPERIMENTAL","Participants will receive 2 days of accelerated TMS (10 treatments per day) to a random location in the prefrontal cortex.",[13],"Device: Transcranial magnetic stimulation",{"label":15,"type":10,"description":16,"interventionNames":17},"TMS to random PFC location 2","After a 2-month washout following arm 1, participants will receive another two days of accelerated iTBS treatment at a different random PFC location.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"TMS to Schizophrenia location","Patients with schizophrenia will be offered to participate in a third arm of the trial, during which participants will receive 2 days of accelerated iTBS to a schizophrenia-specific target.",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DEVICE","Transcranial magnetic stimulation","Accelerated TMS will be provided for 2 days using the same dosing regimen as the FDA-cleared SAINT protocol, ten 9-minute treatments per day.",[19,9,15],null,[30],{"name":31,"affiliation":32,"role":33},"Shan H Siddiqi, MD","Brigham and Women's","PRINCIPAL_INVESTIGATOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":28,"email":39},"Emily Aquadro, MD","CONTACT","857-307-0294","expedition@mgb.org",[41,61],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Acacia Clinics","RECRUITING","Sunnyvale","California","94087","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-122.03635,37.36883,{"lat":53,"lon":52},[56,58],{"name":57,"role":37,"phone":38,"phoneExt":28,"email":39},"Danielle DeSouza, PhD",{"name":59,"role":60,"phone":28,"phoneExt":28,"email":28},"Danielle DeSouza, MD","SUB_INVESTIGATOR",{"facility":5,"status":43,"city":62,"state":63,"zip":64,"country":47,"countryCode":48,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"Boston","Massachusetts","02115",{"type":50,"coordinates":66},[67,68],-71.05977,42.35843,{"lat":68,"lon":67},[71,72],{"name":36,"role":37,"phone":38,"phoneExt":28,"email":39},{"name":73,"role":33,"phone":28,"phoneExt":28,"email":28},"Shan Siddiqi, MD",{"type":33,"investigatorFullName":73,"investigatorTitle":75,"investigatorAffiliation":76,"oldNameTitle":28,"oldOrganization":28},"Principal Investigator","Harvard Medical School (HMS and HSDM)",[78],{"name":79,"class":80},"National Institute of Mental Health (NIMH)","NIH","100545041","phase-2-search-for-novel-transcranial-magnetic-stimulation-tms-targets-for-mental-illness-100545041",false,"NCT06376734","Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness","Transdiagnostic Circuit Mapping of Prefrontal Targets in Accelerated Transcranial Magnetic Stimulation","Expedition","Inclusion Criteria:\n\n* Age 18-65\n* English proficiency sufficient for informed consent, questionnaires\u002Ftasks, and treatment\n* Primary diagnosis of one of the following: major depressive disorder (MDD), obsessive-compulsive disorder (OCD), generalized anxiety disorder (GAD), or schizophrenia (determined by focal assessment using the Structured Clinical Interview for DSM-5)\n\n  * ≥20 on the Beck Depression Inventory for patients with MDD\n  * ≥16 on the Beck Anxiety Inventory for patients with GAD\n  * ≥16 on the Yale-Brown Obsessive-Compulsive Scale for patients with OCD\n  * ≥58 on the Positive and Negative Symptom Scale for patients with schizophrenia\n* Stable psychotropic medication regimen, or remain medication free, for 4 weeks prior to treatment (Medication changes during study enrollment period will be tracked for post hoc analysis).\n* Primary clinician (e.g. psychiatrist, therapist, psychologist, APRN, PA, etc.) responsible for psychiatric care before, during, and after the trial\n\nExclusion Criteria:\n\n* Active pregnancy as determined by a urine pregnancy test\n* Cluster B personality disorders (antisocial personality disorder, borderline personality disorder, histrionic personality disorder, narcissistic personality disorder)\n* PTSD with active, clinically significant symptoms, as determined by clinician\n* Diagnosis of Schizoaffective Disorder, Bipolar Type\n* Recent (within 4 weeks) or concurrent use of rapid-acting antidepressant agent (ketamine\u002Fesketamine\u002FECT)\n* Ferromagnetic metallic implant that would contraindicate receiving TMS or obtaining MRI\n* Any other TMS or MRI safety concerns identified by the clinician\n* Receiving or planning to receive other TMS treatments during course of participation\n* History of:\n\n  * Neurosurgical intervention for mental illness\n  * Moderate to severe autism spectrum disorder\n  * Intellectual disability\n  * Severe cognitive impairment\n  * Significant neurological illness (e.g., dementia, Parkinson's, Huntington's, brain tumor, seizure disorder, subdural hematoma, multiple sclerosis)\n  * Untreated or insufficiently treated endocrine disorder\n  * Eating disorders\n  * Treatment with investigational drug or intervention during the study period\n* Current evidence of:\n\n  * Mania or hypomania\n  * Active suicidal ideation or a suicide attempt within the past year\n  * Contraindications to either TMS or MRI (e.g., metallic implants, etc.).\n  * Current moderate or severe substance use disorder or demonstrating signs of acute substance withdrawal\n  * Significantly increased seizure risk as determined by a clinician\n* For participants with schizophrenia:\n\n  * Evidence of impaired capacity to consent, e.g. impaired insight into illness, as deemed by a licensed psychiatrist or psychologist on the study team\n  * Hospitalization with psychosis in the past 6 months\n* Positive urine drug screen for illicit substances\n* Existing tinnitus (ringing in the ears)\n* Any other condition deemed by the PI to interfere with the study or increase risk to the participant","ALL","18 Years","65 Years",{"count":93,"type":94},180,"ESTIMATED","INTERVENTIONAL",[97],"PHASE2","Participants will receive Transcranial Magnetic Stimulation (TMS) at a random location in the left prefrontal cortex, excluding sites that are potentially unsafe. Extensive behavioral testing will be conducted to determine which behaviors are modulated by stimulating which circuits.",[100,101,102,103,104,105,106,107],"Major Depressive Disorder","Obsessive-Compulsive Disorder","Schizophrenia","Generalized Anxiety Disorder","Mood Disorders","Psychiatric Disorder","Mental Disorder","Depression, Anxiety",[109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124],"depression","anxiety","schizophrenia","OCD","obsessive-compulsive disorder","transcranial magnetic stimulation","TMS","accelerated TMS","accelerated intermittent theta burst stimulation","brain stimulation","neuromodulation","transdiagnostic","neuronavigation","functional connectivity","neuroimaging","theta burst stimulation","2026-02-13",{"date":127,"type":128},"2026-02-17","ACTUAL",{"date":130,"type":128},"2025-01-30",{"date":132,"type":94},"2030-06-01",{"name":5,"class":6},2]